Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

v3.3.1.900
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Net loss $ (8,387,972) $ (1,551,508)
Other comprehensive income (loss):    
Foreign currency translation adjustments 91,211 5,510
Total other comprehensive income 91,211 5,510
Less:    
Net income attributable to non-controlling interests (5,177) (222,484)
Other comprehensive (income) loss attributable to non-controlling interests 32,967 (1,889)
Comprehensive (income) loss attributable to non-controlling interests 27,790 (224,373)
Comprehensive (loss) income attributable to Eyegate Pharmaceuticals, Inc. stockholders $ (8,268,971) $ (1,770,371)